Table IV. Studies investigating TLR7/8 agonist conjugation formulation and adjuvanticity
AdjuvantFormulationModelDisease ModelImmune Response ActivatedReference
SMIP TLR7TLR7 agonist conjugation on RrgB pilus Ag formulated with alumMicePneumococcusImmunization with TLR7 agonist conjugation on RrgB Ag extended animal survival after lethal challenge with S. pneumonia, with 10-fold Ag dose sparing(70)
IMQ-based TLR7/8 agonistParticle-forming polymer-linked adjuvantsMiceOVA and HIVInduction of high-magnitude and persistent local innate immune activation, with associated enhanced CD8+ T cell responses and Th1-skewed Ab responses(71)
IMQ-based TLR7/8 agonistCoupling adjuvant, immunogenic viral protein to nanoparticle-forming thermoresponsive polymersMouse immunization and live viral intranasal challengeRSVElicitation of neutralizing Abs to structure-dependent epitopes on RSV (and other relevant pathogenic Ags)(72)
IMQ-based TLR7 agonist CL307Conjugation to synthetic Pam2C lipopeptide TLR2 agonistMiceHIVEnhanced maturation of human DCs in vitro increased humoral responses against HIV-1 p24 in BALB/c mice in vivo(73)
R848Conjugated to inactivated influenza virus (IPR8-R848)Neonatal NHP African green monkeyInfluenzaTLR7/8-adjvuanted vaccines induced significantly increased virus-specific Ab- and cell-mediated responses, virus clearance, and reduced lung pathologic condition postchallenge, as compared with the nonadjuvanted virus vaccine A/Puerto Rico/8/34(H1N1)(74)